Clinical and Molecular Genetics of the Phosphodiesterases (PDEs)

被引:231
作者
Azevedo, Monalisa F. [1 ,2 ]
Faucz, Fabio R. [1 ,3 ]
Bimpaki, Eirini [1 ]
Horvath, Anelia [1 ]
Levy, Isaac [1 ]
de Alexandre, Rodrigo B. [1 ,3 ]
Ahmad, Faiyaz [4 ]
Manganiello, Vincent [4 ]
Stratakis, Constantine A. [1 ,5 ]
机构
[1] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Sect Endocrinol & Genet, Program Dev Endocrinol & Genet, NIH, Bethesda, MD 20892 USA
[2] Univ Brasilia, Fac Med, Univ Hosp Brasilia, Endocrinol Sect, BR-70840901 Brasilia, DF, Brazil
[3] Pontificia Univ Catolica Parana, Sch Med, Grad Program Hlth Sci, Grp Adv Mol Invest, BR-80215901 Curitiba, Parana, Brazil
[4] NHLBI, Cardiovasc Pulm Branch, NIH, Bethesda, MD 20892 USA
[5] NICHD, Pediat Endocrinol Interinst Training Program, NIH, Bethesda, MD 20892 USA
基金
美国国家卫生研究院;
关键词
CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; CAMP-SPECIFIC PHOSPHODIESTERASE; PULMONARY ARTERIAL-HYPERTENSION; DEPENDENT PROTEIN-KINASE; CGMP-SPECIFIC PHOSPHODIESTERASE; ARYL-HYDROCARBON RECEPTOR; GMP-STIMULATED PHOSPHODIESTERASE; RECESSIVE RETINITIS-PIGMENTOSA; AMP-SPECIFIC PHOSPHODIESTERASE; STATIONARY NIGHT BLINDNESS;
D O I
10.1210/er.2013-1053
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cyclic nucleotide phosphodiesterases (PDEs) are enzymes that have the unique function of terminating cyclic nucleotide signaling by catalyzing the hydrolysis of cAMP and GMP. They are critical regulators of the intracellular concentrations of cAMP and cGMP as well as of their signaling pathways and downstream biological effects. PDEs have been exploited pharmacologically for more than half a century, and some of the most successful drugs worldwide today affect PDE function. Recently, mutations in PDE genes have been identified as causative of certain human genetic diseases; even more recently, functional variants of PDE genes have been suggested to play a potential role in predisposition to tumors and/ or cancer, especially in cAMP-sensitive tissues. Mouse models have been developed that point to wide developmental effects of PDEs from heart function to reproduction, to tumors, and beyond. This review brings together knowledge from a variety of disciplines (biochemistry and pharmacology, oncology, endocrinology, and reproductive sciences) with emphasis on recent research on PDEs, how PDEs affect cAMP and cGMP signaling in health and disease, and what pharmacological exploitations of PDEs may be useful in modulating cyclic nucleotide signaling in a way that prevents or treats certain human diseases.
引用
收藏
页码:195 / 233
页数:39
相关论文
共 483 条
  • [1] Phosphodiesterase 5 inhibitors in rapid ejaculation - Potential use and possible mechanisms of action
    Abdel-Hamid, IA
    [J]. DRUGS, 2004, 64 (01) : 13 - 26
  • [2] TCR- and CD28-mediated recruitment of phosphodiesterase 4 to lipid rafts potentiates TCR signaling
    Abrahamsen, H
    Baillie, G
    Ngai, J
    Vang, T
    Nika, K
    Ruppelt, A
    Mustelin, T
    Zaccolo, M
    Houslay, M
    Taskén, K
    [J]. JOURNAL OF IMMUNOLOGY, 2004, 173 (08) : 4847 - 4858
  • [3] Agents increasing cyclic GMP amplify 5-HT4-elicited positive inotropic response in failing rat cardiac ventricle
    Afzal, Faraz
    Qvigstad, Eirik
    Aronsen, Jan Magnus
    Moltzau, Lise Roman
    Sjaastad, Ivar
    Skomedal, Tor
    Osnes, Jan-Bjorn
    Levy, Finn Olav
    [J]. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2011, 384 (06) : 543 - 553
  • [4] Cyclic Nucleotide Phosphodiesterase 3 Signaling Complexes
    Ahmad, F.
    Degerman, E.
    Manganiello, V. C.
    [J]. HORMONE AND METABOLIC RESEARCH, 2012, 44 (10) : 776 - 785
  • [5] How does cAMP/protein kinase A signaling lead to tumors in the adrenal cortex and other tissues?
    Almeida, Madson Q.
    Stratakis, Constantine A.
    [J]. MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2011, 336 (1-2) : 162 - 168
  • [6] ANANT JS, 1992, J BIOL CHEM, V267, P687
  • [7] Expression of cGMP-specific phosphodiesterase 9A mRNA in the rat brain
    Andreeva, SG
    Dikkes, P
    Epstein, PM
    Rosenberg, PA
    [J]. JOURNAL OF NEUROSCIENCE, 2001, 21 (22) : 9068 - 9076
  • [8] Discovery of a new series of [1,2,4]triazolo[4,3-a]quinoxalines as dual phosphodiesterase 2/phosphodiesterase 10 (PDE2/PDE10) inhibitors
    Andres, Jose-Ignacio
    Buijnsters, Peter
    De Angelis, Meri
    Langlois, Xavier
    Rombouts, Frederik
    Trabanco, Andres A.
    Vanhoof, Greet
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2013, 23 (03) : 785 - 790
  • [9] Phosphodiesterase Type 5 Inhibitors for Pulmonary Arterial Hypertension.
    Archer, Stephen L.
    Michelakis, Evangelos D.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (19) : 1864 - 1871
  • [10] Nonredundant function of phosphodiesterases 4D and 4B in neutrophil recruitment to the site of inflammation
    Ariga, M
    Neitzert, B
    Nakae, S
    Mottin, G
    Bertrand, C
    Pruniaux, MP
    Jin, SLC
    Conti, M
    [J]. JOURNAL OF IMMUNOLOGY, 2004, 173 (12) : 7531 - 7538